(833) 317-6278 
In April 1964, leading cardiologists, cardiovascular surgeons, and pathologists convened in London for a 2-day symposium to discuss a relatively new disease entity that we now know as obstructive hypertrophic cardiomyopathy (HCM). 1 The proceedings kicked off with a comment by the group’s chairman: “I have never before taken part in a discussion in which we start with so few fixed or preconceived ideas. We are in fact launching into poorly charted seas and perhaps we shall end the discussions with a slightly better map.” 2
The New England Journal of Medicine (NEJM) is a prestigious weekly medical journal that serves as a leading authority on healthcare and pharmaceutical research. Published by the Massachusetts Medical Society, NEJM provides physicians, educators, researchers, and other healthcare professionals with peer-reviewed scientific content, expert commentary, and clinical insights.
Covering a wide range of topics within the healthcare and pharmaceutical industries, NEJM's scholarly articles delve into scientific discoveries, medical advancements, health and wellbeing practices, and regulatory policies. The journal's rigorous peer-review process ensures that the published research is backed by robust data and thorough analysis.
In addition to original research studies, NEJM features expert commentary, literature reviews, and legal and regulatory updates, offering readers a comprehensive understanding of the latest developments in the medical field. The journal's content also extends to areas such as food and beverage, and product promotions related to healthcare and pharmaceuticals.
NEJM's audience comprises medical professionals, researchers, academicians, and industry stakeholders who rely on its authoritative content to stay informed, make informed decisions, and advance their knowledge and practice in their respective areas of expertise.
